Quick Answer
Oric Pharmaceuticals, Inc. reported Cash and Equivalents of $45.67 million for fiscal year 2025.
Oric Pharmaceuticals, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $45.67M | -23.1% |
| 2024 | $59.41M | +154.0% |
| 2023 | $23.38M | -65.0% |
| 2022 | $66.84M | -70.4% |
| 2021 | $226.01M | +188.1% |
| 2020 | $78.45M | -12.0% |
| 2019 | $89.16M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $49.67M | +12.3% | -34.5% |
| June 30, 2025 | $75.86M | +52.2% | +53.8% |
| March 31, 2025 | $49.33M | -12.5% | -17.0% |
| December 31, 2024 | $59.41M | +154.0% | +34.3% |
| September 30, 2024 | $44.23M | +68.6% | -11.2% |
| June 30, 2024 | $49.83M | -51.9% | -11.6% |
| March 31, 2024 | $56.36M | -4.5% | +141.0% |
| December 31, 2023 | $23.38M | -65.0% | -10.9% |
- Oric Pharmaceuticals, Inc. showed a decrease of -23.1% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, Oric Pharmaceuticals, Inc.’s cash and equivalents has declined by 48.8% (from $89.16 million to $45.67 million).
- The most recent figure is from Oric Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: